PACB Key Statistics, Chart & Performance
The current stock price of PACB is 2.26 USD. In the past month the price increased by 20.86%. In the past year, price increased by 46.75%.
PACB Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to PACB. When comparing the yearly performance of all stocks, PACB is one of the better performing stocks in the market, outperforming 83.24% of all stocks.
PACB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PACB. PACB may be in some trouble as it scores bad on both profitability and health.
PACB Financial Highlights
Over the last trailing twelve months PACB reported a non-GAAP Earnings per Share(EPS) of -2.2. The EPS decreased by -50.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.71% | ||
| ROE | -1395.49% | ||
| Debt/Equity | 17.88 |
PACB Forecast & Estimates
16 analysts have analysed PACB and the average price target is 2.36 USD. This implies a price increase of 4.37% is expected in the next year compared to the current price of 2.26.
For the next year, analysts expect an EPS growth of -14.91% and a revenue growth 1.67% for PACB
PACB Ownership
About PACB
Company Profile
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 575 full-time employees. The company went IPO on 2010-10-27. The company is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. The company has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Company Info
PACIFIC BIOSCIENCES OF CALIF
1305 O'brien Drive
Menlo Park CALIFORNIA 94025 US
CEO: Christian O. Henry
Employees: 575
Phone: 16505218000
PACIFIC BIOSCIENCES OF CALIF / PACB FAQ
What does PACIFIC BIOSCIENCES OF CALIF do?
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 575 full-time employees. The company went IPO on 2010-10-27. The company is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. The company has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Can you provide the latest stock price for PACIFIC BIOSCIENCES OF CALIF?
The current stock price of PACB is 2.26 USD. The price decreased by -4.64% in the last trading session.
Does PACIFIC BIOSCIENCES OF CALIF pay dividends?
PACB does not pay a dividend.
What is the ChartMill rating of PACIFIC BIOSCIENCES OF CALIF stock?
PACB has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists PACB stock?
PACB stock is listed on the Nasdaq exchange.
How is the valuation of PACIFIC BIOSCIENCES OF CALIF (PACB) based on its PE ratio?
PACIFIC BIOSCIENCES OF CALIF (PACB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.2).
What is the employee count for PACB stock?
PACIFIC BIOSCIENCES OF CALIF (PACB) currently has 575 employees.